tirzepatide make you tired Mounjaro fatigue: Causes and how to manage it Do GLP-1 Medications Cause Fatigue?

Real-world data suggests women in menopause achieve weight loss similar to younger cohorts, but hormonal fluctuations during perimenopause may increase variability in response

22.5% weight loss in SURMOUNT-1 Phase III

She has served as lead investigator and author for trials investigating novel nutrient-stimulated hormone (NuSH)-based therapies for obesity including dual hormone receptor agonist, tirzepatide, a GIP/GLP-1 receptor agonist (Jastreboff, et al ., NEJM , 2022 and NEJM , 2024), triple hormone receptor agonist, retatrutide, a GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al ., NEJM , 2023), and a monthly monoclonal antibody peptide conjugate, maridebart cafraglutide, a GIP receptor antagonist GLP-1 receptor agonist (Jastreboff, et, al., NEJM, 2025)

References Sikiric P, Seiwerth S, et al